TickerTalks
Browse all tickers →
TickerTalks›$DVA
DVDVA

DaVita Inc.

$DVA·$12B·Medical - Care Facilities·Healthcare
$180.06+0.5%YTD+100.6%1Y+34.0%
Mentions · last 7 days
2026-08-07: 9 posts2026-08-08: 4 posts2026-08-09: 3 posts2026-08-10: 3 posts2026-08-11: 4 posts2026-08-12: 9 posts2026-08-13: 3 posts35-59%
Price updated 17h ago·X counts updated 2d ago
DVDVA
$DVADaVita Inc.
$180.06+0.50%35 posts-59%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $DVA, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-08-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

DaVita Q2 EPS beat but stock dropped 20% — Berkshire sold $36.5M days before the print, and value buyers are loading on the pullback.

DaVita Inc is the largest US dialysis provider — the specific franchise that has been in a specific Berkshire-owned position for years, and Buffett's continued reduction is the specific structural signal alongside the Q2 print-plus-margin-cracks combination.

  • The Q2 mechanics were mechanically strong: revenue of $3.55B grew (comp base) at a 31% gross margin and 15% operating margin, EPS of $4.02 beat consensus of $3.88 by 3.6%, and $219M of quarterly free cash flow at a 10.9% FCF yield — for a business at just 21x TTM PE and 0.99x sales with 11% ROIC and consensus FY26 EPS of $14.88 putting the forward at ~12x, the mechanics support the coiled-with-upward-bias framing after the -20% post-print sell-off.
  • The Berkshire selling is the specific structural signal: Berkshire Hathaway sold $36.5M on Jul 31 (182,980 shares at $199.55) — that's just days before the stock dropped 20% on earnings, and posters caustically note the specific timing. It's a specific caution flag but Berkshire has been reducing the position for multiple quarters, so it's not necessarily a specific incremental warning.
  • The competitor-closing-plus-share-gain narrative is the specific structural bull anchor: a competitor closing up shop and DaVita taking share (per posters) plus the described "good 10Q" and market-overreaction framing supports the value-hunt setup — plus the tape at 53rd percentile of range and -17% vs the 50-day is the specific dislocation buyers are anchoring on.

What resolves the coil upward is the Oct 28 print confirming Q2's margin trajectory holds plus specific commentary on share-gains from competitor exits; what breaks it down is continued Berkshire selling or a specific margin-compression signal that reveals the operating economics can't defend the current level.

Agrees with X sentimentThe mixed X read has the specific facts right — Buffett selling another $36M of DaVita just days before the stock dropped 20% on earnings, value buyers loading on the pullback citing a competitor closing up shop and DaVita taking share, described 'good 10Q' and market overreaction framing, and the sentiment split between buying-opportunity cheerers and insider-warning trackers are all real reflections of the actual debate.

What to watch: Oct 28 Q3 earnings — margin trajectory, share-gain commentary from competitor exits, and any additional Berkshire disclosure. Continued Berkshire selling or margin-compression signal is what breaks the coil down.

On the calendar: 2026-10-28 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment5 posts analyzed · as of 2026-08-12

Buffett sold another $36M of DaVita just days before the stock dropped 20% on earnings, and posters caustically note the timing. Value buyers are loading on the pullback citing a competitor closing up shop and DaVita taking share, with a described 'good 10Q' and market overreaction. Sentiment is split between those cheering the sell-off as a buying opportunity and those tracking the insider warning.

Read the AI verdict + X sentiment for $DVA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Operates the largest U.S. network of outpatient kidney dialysis centers, providing renal care management to chronic kidney failure patients.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $DVA.

Medical - Care Facilities · Healthcare

No material change from last week — hospital systems continue to rely on travel nursing and locum physician staffing to fill permanent workforce gaps that training pipelines cannot replenish at..

What this means for $DVA

Neutral — Operates the largest U.S. network of outpatient kidney dialysis centers, providing renal care management to chronic kidney failure patients; limited read-through from medical - care facilities macro dynamics to this specific revenue mix.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.6%YTD
+29.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
21.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
10.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
15.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
10.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-133%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
31.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-17.5Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$4.02$3.88+3.6%
Q1 2026May 5, 2026$2.87$2.41+19.1%
Q4 2025Feb 2, 2026$3.40$3.24+4.9%
Q3 2025Oct 29, 2025$2.51$3.17-20.8%
Next earningsWed, Oct 28·consensus EPS $3.78

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.4B+6.0%31.4%14.1%$2.93$218.8M
Q4 FY25$3.6B+9.9%28.3%15.2%$2.51$395.3M
Q3 FY25$3.4B+4.8%31.8%14.8%$2.09$675.3M
Q2 FY25$3.4B+6.1%33.1%15.9%$2.62$203.3M

Forward consensus

4-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$14.1B$13.9B – $14.3B$14.88$14.33 – $15.835
FY27$14.5B$14.3B – $14.9B$17.33$16.15 – $18.485
FY28$14.6B$14.0B – $15.4B$19.16$18.26 – $20.073
FY29$15.9B$15.6B – $16.4B$18.12$17.62 – $18.922

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.54%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+12.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 62.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.875-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 31Berkshire Hathaway Inc10% owner183.0K sh$36.5MSellJun 16Javier RodriguezCEO39.4K sh$8.2MSellJun 15Waters Kathleen AlyceChief Legal & Pub. Affairs Off15.4K sh$3.2MSellJun 15Javier RodriguezCEO30.0K sh$6.3MSellMay 15James O HeartyChief Compliance Officer15.0K sh$2.9MSellMay 12Maughan David PaulCOO13.5K sh$2.7MSellMay 11Maughan David PaulCOO7.1K sh$1.4MSellMay 7Joel AckermanCFO51.5K sh$9.9MSellMay 6James O HeartyChief Compliance Officer2.2K sh$382KSellMay 1Berkshire Hathaway Inc10% owner1.2M sh$182.9M
+ 29 other (21 awards · 5 inkinds · 1 gift · 1 return · 1 exempt) in window

See when $DVA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJun 88-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 5.07: Shareholder vote
AI summary

DaVita Inc. (DVA) filed an 8-K on June 8, 2026 reporting a Ninth Amendment to its Credit Agreement with JPMorgan Chase as agent, adding $500 million in incremental borrowings under the existing Tranche B-2 senior secured term loan 'B' facility maturing May 2031. The incremental term loan bears interest at Term SOFR plus an applicable margin. This $500M debt add-on is material — it increases DaVita's leverage while signaling management's confidence in the dialysis provider's cash flow to service additional term debt.

+ 9 other (2 10-Qs · 2 earnings 8-Ks · 2 proxys · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Is DaVita (DVA) a Great Value Stock Right Now?zacks.com·9d agoDaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Downzacks.com·10d agoDVA Q2 Earnings Call Centers on Clinical-Led Volume Growthzacks.com·10d agoDaVita Q2 Earnings Call Highlightsmarketbeat.com·11d agoDaVita Inc (DVA) (Q2 2026) Earnings Call Highlights: Strong Volume Growth and Strategic Execution Drive Confidencegurufocus.com·11d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$STLN$AVAH$THC$NUTX$PIII$AMN$HCA$PACS
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport